How much did Vitrolife achieve in EBIT for the current year?
In the current year, Vitrolife has achieved an EBIT of 929 M SEK.
Vitrolife EBIT 2025
Vitrolife EBIT
929 M SEK
Ticker
VITR.ST
ISIN
SE0011205202
WKN
A2JLT3
In 2025, Vitrolife's EBIT was 929 M SEK, a 16.32% increase from the 798.66 M SEK EBIT recorded in the previous year.
The Vitrolife EBIT history
| YEAR | EBIT (undefined SEK) |
|---|---|
| 2026e | 1.07 |
| 2025e | 0.93 |
| 2024e | 0.8 |
| 2023 | 0.74 |
| 2022 | 0.65 |
| 2021 | 0.43 |
| 2020 | 0.37 |
| 2019 | 0.49 |
| 2018 | 0.41 |
| 2017 | 0.34 |
| 2016 | 0.25 |
| 2015 | 0.23 |
| 2014 | 0.14 |
| 2013 | 0.08 |
| 2012 | 0.05 |
| 2011 | 0.04 |
| 2010 | 0.04 |
| 2009 | 0.03 |
| 2008 | 0.02 |
| 2007 | 0.02 |
| 2006 | 0.02 |
| 2005 | 0.01 |
| 2004 | 0.01 |
Vitrolife Revenue, EBIT, Net Income SE0011205202 · A2JLT3
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Vitrolife, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Vitrolife from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Vitrolife’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Vitrolife. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Vitrolife’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Vitrolife’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Vitrolife’s growth potential.
Vitrolife Revenue, EBIT and net profit per share
| Date | Vitrolife Revenue | Vitrolife EBIT | Vitrolife Net Income |
|---|---|---|---|
| 2026e | 4.36 B undefined | 1.07 B undefined | 783.36 M undefined |
| 2025e | 4 B undefined | 929 M undefined | 664.82 M undefined |
| 2024e | 3.67 B undefined | 798.66 M undefined | 544.35 M undefined |
| 2023 | 3.51 B undefined | 738 M undefined | -3.85 B undefined |
| 2022 | 3.23 B undefined | 652 M undefined | 394 M undefined |
| 2021 | 1.68 B undefined | 425.73 M undefined | 340.97 M undefined |
| 2020 | 1.25 B undefined | 367.11 M undefined | 286.85 M undefined |
| 2019 | 1.48 B undefined | 488.26 M undefined | 382.79 M undefined |
| 2018 | 1.15 B undefined | 414.16 M undefined | 309.7 M undefined |
| 2017 | 1.05 B undefined | 337.64 M undefined | 263.64 M undefined |
| 2016 | 856.11 M undefined | 248.21 M undefined | 190.37 M undefined |
| 2015 | 722.37 M undefined | 227.39 M undefined | 182.85 M undefined |
| 2014 | 510.5 M undefined | 143.3 M undefined | 109.1 M undefined |
| 2013 | 452.7 M undefined | 77.5 M undefined | 56.3 M undefined |
| 2012 | 362 M undefined | 48.3 M undefined | 333.8 M undefined |
| 2011 | 356.1 M undefined | 41.9 M undefined | 30.4 M undefined |
| 2010 | 297.6 M undefined | 36.2 M undefined | 28.9 M undefined |
| 2009 | 274.6 M undefined | 32.1 M undefined | 34.1 M undefined |
| 2008 | 225.1 M undefined | 23.5 M undefined | 30 M undefined |
| 2007 | 188.9 M undefined | 21 M undefined | 36.1 M undefined |
| 2006 | 171.3 M undefined | 20 M undefined | 15.2 M undefined |
| 2005 | 120.1 M undefined | 12 M undefined | 14.9 M undefined |
| 2004 | 103.9 M undefined | 13.4 M undefined | 11.9 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 103.9 M SEK | 13.4 M SEK | 11.9 M SEK |
| 2005 | 120.1 M SEK | 12 M SEK | 14.9 M SEK |
| 2006 | 171.3 M SEK | 20 M SEK | 15.2 M SEK |
| 2007 | 188.9 M SEK | 21 M SEK | 36.1 M SEK |
| 2008 | 225.1 M SEK | 23.5 M SEK | 30 M SEK |
| 2009 | 274.6 M SEK | 32.1 M SEK | 34.1 M SEK |
| 2010 | 297.6 M SEK | 36.2 M SEK | 28.9 M SEK |
| 2011 | 356.1 M SEK | 41.9 M SEK | 30.4 M SEK |
| 2012 | 362 M SEK | 48.3 M SEK | 333.8 M SEK |
| 2013 | 452.7 M SEK | 77.5 M SEK | 56.3 M SEK |
| 2014 | 510.5 M SEK | 143.3 M SEK | 109.1 M SEK |
| 2015 | 722.37 M SEK | 227.39 M SEK | 182.85 M SEK |
| 2016 | 856.11 M SEK | 248.21 M SEK | 190.37 M SEK |
| 2017 | 1.05 B SEK | 337.64 M SEK | 263.64 M SEK |
| 2018 | 1.15 B SEK | 414.16 M SEK | 309.7 M SEK |
| 2019 | 1.48 B SEK | 488.26 M SEK | 382.79 M SEK |
| 2020 | 1.25 B SEK | 367.11 M SEK | 286.85 M SEK |
| 2021 | 1.68 B SEK | 425.73 M SEK | 340.97 M SEK |
| 2022 | 3.23 B SEK | 652 M SEK | 394 M SEK |
| 2023 | 3.51 B SEK | 738 M SEK | -3.85 B SEK |
| 2024e | 3.67 B SEK | 798.66 M SEK | 544.35 M SEK |
| 2025e | 4 B SEK | 929 M SEK | 664.82 M SEK |
| 2026e | 4.36 B SEK | 1.07 B SEK | 783.36 M SEK |
Vitrolife stock margins SE0011205202 · A2JLT3
The Vitrolife margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vitrolife. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vitrolife.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Vitrolife's sales revenue. A higher gross margin percentage indicates that the Vitrolife retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Vitrolife's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Vitrolife's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Vitrolife's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Vitrolife. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Vitrolife's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Vitrolife Margin History
| Vitrolife Gross margin | Vitrolife Profit margin | Vitrolife EBIT margin | Vitrolife Profit margin |
|---|---|---|---|
| 2026e | 56.32 % | 24.43 % | 17.95 % |
| 2025e | 56.32 % | 23.21 % | 16.61 % |
| 2024e | 56.32 % | 21.78 % | 14.84 % |
| 2023 | 56.32 % | 21.01 % | -109.65 % |
| 2022 | 55.04 % | 20.16 % | 12.18 % |
| 2021 | 62.24 % | 25.33 % | 20.29 % |
| 2020 | 61.63 % | 29.47 % | 23.03 % |
| 2019 | 63.42 % | 32.99 % | 25.86 % |
| 2018 | 66.11 % | 35.97 % | 26.9 % |
| 2017 | 65.16 % | 32.27 % | 25.2 % |
| 2016 | 65.56 % | 28.99 % | 22.24 % |
| 2015 | 67.16 % | 31.48 % | 25.31 % |
| 2014 | 68.38 % | 28.07 % | 21.37 % |
| 2013 | 66.4 % | 17.12 % | 12.44 % |
| 2012 | 65.83 % | 13.34 % | 92.21 % |
| 2011 | 66.92 % | 11.77 % | 8.54 % |
| 2010 | 69.29 % | 12.16 % | 9.71 % |
| 2009 | 70.25 % | 11.69 % | 12.42 % |
| 2008 | 69.39 % | 10.44 % | 13.33 % |
| 2007 | 68.61 % | 11.12 % | 19.11 % |
| 2006 | 68.07 % | 11.68 % | 8.87 % |
| 2005 | 69.03 % | 9.99 % | 12.41 % |
| 2004 | 71.61 % | 12.9 % | 11.45 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 71.61 % | 12.9 % | 11.45 % |
| 2005 | 69.03 % | 9.99 % | 12.41 % |
| 2006 | 68.07 % | 11.68 % | 8.87 % |
| 2007 | 68.61 % | 11.12 % | 19.11 % |
| 2008 | 69.39 % | 10.44 % | 13.33 % |
| 2009 | 70.25 % | 11.69 % | 12.42 % |
| 2010 | 69.29 % | 12.16 % | 9.71 % |
| 2011 | 66.92 % | 11.77 % | 8.54 % |
| 2012 | 65.83 % | 13.34 % | 92.21 % |
| 2013 | 66.4 % | 17.12 % | 12.44 % |
| 2014 | 68.38 % | 28.07 % | 21.37 % |
| 2015 | 67.16 % | 31.48 % | 25.31 % |
| 2016 | 65.56 % | 28.99 % | 22.24 % |
| 2017 | 65.16 % | 32.27 % | 25.2 % |
| 2018 | 66.11 % | 35.97 % | 26.9 % |
| 2019 | 63.42 % | 32.99 % | 25.86 % |
| 2020 | 61.63 % | 29.47 % | 23.03 % |
| 2021 | 62.24 % | 25.33 % | 20.29 % |
| 2022 | 55.04 % | 20.16 % | 12.18 % |
| 2023 | 56.32 % | 21.01 % | -109.65 % |
| 2024e | 56.32 % | 21.78 % | 14.84 % |
| 2025e | 56.32 % | 23.21 % | 16.61 % |
| 2026e | 56.32 % | 24.43 % | 17.95 % |
Vitrolife Aktienanalyse
What does Vitrolife do?
Vitrolife AB is a Swedish biotech company specializing in the development and marketing of products for in vitro fertilization (IVF) and regenerative medicine. It was founded in 1994 and has over 390 employees worldwide. The company's main business is IVF, offering a wide range of essential products for IVF treatment such as culture media, devices for semen analysis and preparation, embryo transfer techniques, and products for biopsy examinations and cryopreservation. Vitrolife has a presence in 110 countries and has expanded its market to China where there is a high demand for fertility treatments. The company also offers medical equipment for regenerative treatments. Vitrolife is a leading player in the IVF industry known for its high product quality and innovation. It collaborates with universities and research institutions globally to improve IVF technology and success rates. The company places importance on sustainability and environmental protection, using 100% animal-free ingredients in their culture media and practicing recycling and waste reduction in their production facilities. In summary, Vitrolife offers a wide range of products for IVF and regenerative medicine, with a focus on supporting IVF treatments. The company is a leader in its industry and actively participates in research. It is committed to sustainability and environmental responsibility. Vitrolife ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Vitrolife's EBIT
Vitrolife's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Vitrolife's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Vitrolife's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Vitrolife’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Vitrolife stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Vitrolife.
How has the EBIT of Vitrolife developed in recent years?
The EBIT of Vitrolife has increased by 16.32% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Vitrolife?
The EBIT of Vitrolife is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Vitrolife pay?
Over the past 12 months, Vitrolife paid a dividend of 0.85 SEK . This corresponds to a dividend yield of about 0.4 %. For the coming 12 months, Vitrolife is expected to pay a dividend of 0.86 SEK.
What is the dividend yield of Vitrolife?
The current dividend yield of Vitrolife is 0.4 %.
When does Vitrolife pay dividends?
Vitrolife pays a quarterly dividend. This is distributed in the months of May, May, May, June.
How secure is the dividend of Vitrolife?
Vitrolife paid dividends every year for the past 6 years.
What is the dividend of Vitrolife?
For the upcoming 12 months, dividends amounting to 0.86 SEK are expected. This corresponds to a dividend yield of 0.41 %.
In which sector is Vitrolife located?
Vitrolife is assigned to the 'Health' sector.
Wann musste ich die Aktien von Vitrolife kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Vitrolife from 5/14/2024 amounting to 1 SEK, you needed to have the stock in your portfolio before the ex-date on 5/7/2024.
When did Vitrolife pay the last dividend?
The last dividend was paid out on 5/14/2024.
What was the dividend of Vitrolife in the year 2024?
In the year 2024, Vitrolife distributed 0.85 SEK as dividends.
In which currency does Vitrolife pay out the dividend?
The dividends of Vitrolife are distributed in SEK.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Vitrolife
Our stock analysis for Vitrolife Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vitrolife Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
